Finanzen von Alpha Teknova Inc (TKNO)TKNOAlpha Teknova Inc

Alpha Teknova, Inc. (TKNO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Lab Essentials, accounting for 75.8% of total sales, equivalent to $8.39M. Other significant revenue streams include Clinical Solutions and Other. Understanding this composition is critical for investors evaluating how TKNO navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Alpha Teknova, Inc. maintains a gross margin of 37.73%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -23.72%, while the net margin is -26.02%. These profitability ratios, combined with a Return on Equity (ROE) of -24.19%, provide a clear picture of how effectively TKNO converts its operational activities into shareholder value.

In the context of the broader market, TKNO competes directly with industry leaders such as CUVL and TRXB. With a market capitalization of $379.47M, it holds a leading position in the sector. When comparing efficiency, TKNO's gross margin of 37.73% stands against CUVL's N/A and TRXB's N/A. Such benchmarking helps identify whether Alpha Teknova, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown improving gross margins, with Q2 2026 gross margin at 37.73%, up from 19.87% in Q4 2024, reflecting better cost management and revenue generation.